Impact Factor
2.91
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.82
196 total citations
h5-index
19
h5 depth signal
Cited share
59.8%
70 of 117
Total citations
196
Citation footprint
Metric signal
2.67
External metric anchor
Self-citation
3.1%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
334
China
156
India
58
Thailand
33
South Korea
12
Citing Fields of Research
Virology
48
Phytochemicals
47
Pharmacology & Toxicology
36
Drug Delivery Systems
35
Diabetes
31
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
875
Articles tracked across the journal lifetime
Indexed publication set
117
70 cited publications
Last 12 months
63
10.5 publications/month
Open access share
84.1%
53 OA publications in the last year
Leading citing country
Japan
334 citing publications
Leading citing field
Virology
48 citing publications
Latest tracked publication
31 August 2026
10 recent records available
Coverage & Indexing History
v6n1, Feb. 2012-
v6n1, Feb. 2012- ; selected citations only before this date
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Diabetes
Musculoskeletal Disorders
Antibiotic & Antibacterial Agents
Anesthetic & Pain Medicine
Wounds & Ulcers
Fungal Pathogenesis
Issuing & Sponsoring Bodies
Contributor
Shandong da xue zhong ri yao wu shai xuan zhongxin
Contributor
International Advancement Center for Medicine & Health Research
Broad Categories
Drug Therapy
Pharmacology
Human Reproduction
Drug Delivery Systems
Hematology
Wounds & Ulcers
Antibiotic & Antibacterial Agents
Virology
Medical Ethics
MeSH Descriptors
Drug Discovery
Drug Therapy
Technology, Pharmaceutical
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
03
DOI 10.5582/ddt.2026.01050
Open DOI
Unveiling the allosteric inhibition mechanism of SARS-CoV-2 main protease and discovery of a novel allosteric inhibitor
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) is a crucial therapeutic target for anti-coronavirus disease 2019 (COVID-19) drug development, as it is essential for viral replication. However, mutat...
04
DOI 10.5582/ddt.2026.01045
Open DOI
Duzhong Fang (DZF) alleviates rotenone-induced Parkinson's disease-like pathological alterations through regulation of the gut-brain axis via the intestinal TPH1/5-HT pathway
The gut-brain axis is increasingly recognized as a critical pathway in Parkinson's disease (PD), but the gut-targeted mechanisms underlying the therapeutic effects of herbal formulas remain poorly understood. In this study, an enterogeni...
05
DOI 10.5582/ddt.2026.01033
Open DOI
Simultaneous determination of belzutifan and cabozantinib, oral agents for renal cell carcinoma, in human plasma using high-performance liquid chromatography
Belzutifan and cabozantinib are oral drugs for advanced renal cell carcinoma, which display exposure-dependent toxicities. No validated method exists for simultaneously quantifying these drugs in human plasma. In this study, we developed...
06
DOI 10.5582/ddt.2026.01040
Open DOI
Disproportionality analysis of opioid-related urinary retention using the JADER database: Focus on the lack of signal for transdermal fentanyl
Urinary retention is a known adverse effect of opioids, but limited information is available on how this adverse event varies among individual opioids. This study evaluated disproportionality signals between major opioids and urinary ret...
07
DOI 10.5582/ddt.2026.01034
Open DOI
Nicotine administration selectively inhibits kainate-induced Arc and junB but not c-fos and egr1 mRNA expression in mouse cerebral cortex
The nicotinic acetylcholine receptor is an ion channel receptor that is highly expressed in the brain and can cooperatively propagate several signals with other ion channel receptors in neurons. However, little is known about how nicotin...
08
DOI 10.5582/ddt.2026.01056
Open DOI
Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1)
Narcolepsy type 1 (NT1) is a chronic neurological disorder caused by selective loss of orexin-producing neurons, resulting in unstable sleep-wake regulation and characteristic symptoms including excessive daytime sleepiness (EDS), catapl...
09
DOI 10.5582/ddt.2026.01036
Open DOI
Sensory testing assessment of dosage forms designed to resist overdose
Overdose incidence has increased among young individuals, particularly involving psychotropic and over-the-counter (OTC) drugs. However, there is limited information regarding how the physical form of medications—such as tablet size or t...
10
DOI 10.5582/ddt.2026.01051
Open DOI
Enlicitide: The first oral PCSK9 inhibitor approved for treatment of hypercholesterolemia
Hypercholesterolemia, and particularly elevated low-density lipoprotein cholesterol (LDL-C), is a major causal factor in atherosclerotic cardiovascular disease (ASCVD) and contributes substantially to coronary heart disease, ischemic str...
Bibliographical & Catalog Notes
Description based on: Vol. 2, no. 1 (Feb. 2008); title from cover.
Latest issue consulted: Vol. 2, no. 2 (Apr. 2008).
Also issued online.